Overview of WHO Public Assessment Report (WHOPAR)

  HA358 - Lamivudine/Stavudine+Efavirenz - 150mg/40mg Tablets + 600mg Film-coated tablets -
       Ranbaxy Laboratories Ltd - INDIA

IMPORTANT - Note for all prequalified products containing 40 mg stavudine

• Part 2

• Part 3

• Part 4

• Part 5

• Part 8

Part 1 – Abstract
Part 2 – Presentation
Part 3 – Product Information Leaflet
Part 4 – Summary of Product Characteristics
Part 5 – Label
Part 6 – Discussion
Part 7 – Steps before Prequalification
Part 8 – Steps following Prequalification

Samples of the artworks of the SPC/PIL/labelling have not been submitted. Therefore, control of compliance with WHOPAR guidelines (contents and format) has not been possible.